Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectable Naltrexone and Oral Bupropion in Schizophrenia Smokers
NCT06374290Phase 1Terminated
- Sponsor
- UTHealth Houston
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of naltrexone and bupropion in nicotine dependence, sponsored by UTHealth Houston. Primary endpoints: Feasibility as assessed by the percentage of participants that enroll in the study at 3 weeks, Percentage of participants that complete 3 weeks of treatment and 1 more. Started Jul 2024; status: terminated.
02
Drugs
naltrexonebupropion
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT06374290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374290.